Norethindrone enanthate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Norethindrone enanthate is a synthetic progestogen indicated for contraceptive therapy.

Generic Name
Norethindrone enanthate
DrugBank Accession Number
DB14678
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 410.598
Monoisotopic: 410.282095084
Chemical Formula
C27H38O3
Synonyms
  • Norethisterone enanthate
  • Norethisterone oenanthate
External IDs
  • LG 202
  • SH 393
  • SH-8.0393
  • ZK-5410

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to preventPregnancyCombination Product in combination with: Estradiol valerate (DB13956)••••••••••••••••••••••••••• ••••••••• ••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Norethindrone enanthate can be increased when it is combined with Abametapir.
AbciximabThe risk or severity of adverse effects can be increased when Norethindrone enanthate is combined with Abciximab.
AcenocoumarolThe risk or severity of adverse effects can be increased when Norethindrone enanthate is combined with Acenocoumarol.
AcetaminophenThe metabolism of Norethindrone enanthate can be increased when combined with Acetaminophen.
AcetazolamideThe metabolism of Norethindrone enanthate can be increased when combined with Acetazolamide.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
NorethisteroneprodrugT18F433X4S68-22-4VIKNJXKGJWUCNN-XGXHKTLJSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
MESIGYNA 5 MG+50 MG/1 ML ENJEKSIYONLUK COZELTI ICEREN KULLANIMANorethindrone enanthate (50 mg/ml) + Estradiol valerate (5 mg/ml)Injection, solutionIntramuscularBAYER TÜRK KİMYA SAN. LTD. ŞTİ.1999-08-06Not applicableTurkey flag
MESIGYNA®Norethindrone enanthate (50 mg) + Estradiol valerate (5 mg)SolutionIntramuscularBAYER A.G.2006-11-102021-04-01Colombia flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
HY3S2K0J0F
CAS number
3836-23-5
InChI Key
APTGJECXMIKIET-WOSSHHRXSA-N
InChI
InChI=1S/C27H38O3/c1-4-6-7-8-9-25(29)30-27(5-2)17-15-24-23-12-10-19-18-20(28)11-13-21(19)22(23)14-16-26(24,27)3/h2,18,21-24H,4,6-17H2,1,3H3/t21-,22+,23+,24-,26-,27-/m0/s1
IUPAC Name
(1R,3aS,3bR,9aR,9bS,11aS)-1-ethynyl-11a-methyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl heptanoate
SMILES
[H][C@@]12CC[C@@](OC(=O)CCCCCC)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]

References

General References
  1. NPRA Product Information: NORISTERAT (norethindrone enanthate) intramuscular injection [Link]
KEGG Compound
C14486
ChemSpider
199613
RxNav
31984
ChEBI
34894
ChEMBL
CHEMBL3187229
ZINC
ZINC000004217172
Wikipedia
Norethisterone_enanthate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionBacterial Vaginosis (BV) / Human Immunodeficiency Virus (HIV) Infections1
1CompletedBasic SciencePharmacokinetics1
Not AvailableCompletedNot AvailableContraceptive1
Not AvailableNot Yet RecruitingHealth Services ResearchContraception Behavior / Contraceptive Usage1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntramuscular
InjectionIntramuscular200 mg/ml
SolutionIntramuscular
Injection, solutionIntramuscular
SolutionIntramuscular; Parenteral
SolutionParenteral
SolutionIntramuscular50 mg
SolutionParenteral200.000 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00148 mg/mLALOGPS
logP5.43ALOGPS
logP6.14Chemaxon
logS-5.4ALOGPS
pKa (Strongest Acidic)18.25Chemaxon
pKa (Strongest Basic)-4.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area43.37 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity119.61 m3·mol-1Chemaxon
Polarizability49.66 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001a-2090100000-cbaaef1cad38452bee69
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0bt9-0710900000-41c0fd8ec0548c9354eb
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-08gl-8790000000-afc6dfb2eb7d99215090
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001j-3290000000-94586e403689e504a480
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pbc-9210000000-1626bc1d7d768f107acd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-9010000000-d4725436adbf90d73401
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-216.5123271
predicted
DarkChem Lite v0.1.0
[M-H]-204.39027
predicted
DeepCCS 1.0 (2019)
[M+H]+215.8657271
predicted
DarkChem Lite v0.1.0
[M+H]+207.68788
predicted
DeepCCS 1.0 (2019)
[M+Na]+216.0223271
predicted
DarkChem Lite v0.1.0
[M+Na]+215.00453
predicted
DeepCCS 1.0 (2019)

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhang N, Shon J, Kim MJ, Yu C, Zhang L, Huang SM, Lee L, Tran D, Li L: Role of CYP3A in Oral Contraceptives Clearance. Clin Transl Sci. 2018 May;11(3):251-260. doi: 10.1111/cts.12499. Epub 2017 Oct 6. [Article]

Drug created at September 05, 2018 17:00 / Updated at May 14, 2021 01:07